Can Amgen bone drug Evenity make a comeback? FDA, analysts aren't so sure

Amgen osteoporosis candidate Evenity is trying to score an approval after cardiovascular red flags derailed it in mid-2017. But analysts aren’t so optimistic, and FDA review documents posted Monday suggest the drug has an uphill battle for approval.